Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATA3219 in R/R B-cell Non-Hodgkin Lymphoma
NCT06256484Phase 1Terminated
- Sponsor
- Atara Biotherapeutics
- Start
- Sep 2024
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of ATA3219 in B-cell non-Hodgkin lymphoma, sponsored by Atara Biotherapeutics. Primary endpoints: Incidence and Severity of Treatment-emergent Adverse Events at 90 days, Incidence and Severity of Adverse Events of Special Interest at 90 days and 4 more. Started Sep 2024; status: terminated.
02
Drugs
ATA3219
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06256484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256484.